Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

BACKGROUND: 131-iodine ((131)I) administration after surgery remains a standard practice in differentiated thyroid cancer (DTC). In 2014, the American Thyroid Association presented new guidelines for the staging and management of DTC, including no systematic (131)I in patients at low-risk of recurre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thyroid Res
Autors principals: Iconaru, Laura, Baleanu, Felicia, Taujan, Georgiana, Duttmann, Ruth, Spinato, Linda, Karmali, Rafik, Bergmann, Pierre, Hambye, Anne-Sophie
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7488699/
https://ncbi.nlm.nih.gov/pubmed/32944083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13044-020-00089-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars